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Abstract
Background: Global epidemic of diabetes is a serious health care concern because of its complications and
consequently reduced life expectancy and increased morbidity. However, the bone turnover and thus bone
health may be affected or even compromised by diabetes and its complications. The aim of this study was
to assess whether bone turnover markers are associated with diabetes micro-vascular complications.
Methods: A total of 204 type 2 diabetes patients (104 patients with diabetic micro-vascular complications
(retinopathy and/or nephropathy) as a case group and 100 patients without retinopathy and/or nephropathy)
as a control group were recruited in this case–control study. The biochemical and metabolic parameters and
bone turnover markers were assessed in all patients.
Results: Our findings showed serum levels of osteocalcin (OC) (p = 0.0001) and, carboxy-terminal collagen
crosslinks (CTX) (p = 0.006) were higher in diabetic patients with both diabetic retinopathy and nephropathy
compared with control group. However, there was no significant difference in serum levels of procollagen I
aminoterminal propeptide (P1NP) between diabetic patients with diabetic retinopathy (DR) and/or diabetic
nephropathy (DN) compared with control.
In diabetes patients with complications, there were significant negative correlation between OC and CTX with
estimated-glomerular filtration rate (e-GFR) and also positive correlation between each bone marker (OC and
CTX) and PTH levels (p = 0.0001) and BUN (p = 0.0001).
In a general linear model, after adjusting for age, sex and BMI, and microvascular complications, there was
not any significant association between three bone turnover markers and metabolic markers including fasting
glucose, insulin, and lipid profile. Among kidney markers, there were significant positive associations between
serum levels of CTX and OC with BUN (p < 0.05) as well as PTH (p < 0.0001).
Conclusions: Our data suggest the possible role of PTH and BUN levels in modulating bone turnover markers
in diabetic patients.
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Background
Osteoporosis, known as the silent disease, has become an
important public health issue and highly prevalent condi-
tion affecting hundreds of millions of people around the
world. It is characterized by reduced bone mass and al-
tered microarchitecture [1]. Aging is the most significant
risk factor for osteoporosis. Considering the global trend
in population aging, skeletal health is an important con-
sideration for older adults in general and health priority in
worldwide [2].
Type 2 diabetes (T2D) is a common age-related disorder
that imposes a growing medical and economic burden in
ageing populations. Growing evidence suggests that pa-
tients with type 2 diabetes are at increased risk of bone fra-
gility [3, 4]. Several studies have demonstrated increased
risk of fracture in diabetic patients in spite of normal or
even higher bone mineral density (BMD). Longer disease
duration, poor glycemic control and particularly diabetic
complications could increase the fracture risk in diabetic
patients [3]. A few studies have addressed the association of
chronic complications of T2D with reduced BMD. They
have reported decreased BMD in patients with neuropathy
[4, 5], retinopathy [6] and also in patients with early-stage
of diabetic chronic kidney disease [7]. Recent studies have
demonstrated that diabetes may adversely influence the
bone quality through the regulation of bone cells [8].
Bone turnover markers (BTMs) are peptides secreted
by bone cells and reflect both bone formation (osteocal-
cin, procollagen I aminoterminal propeptide) and bone
resorption (carboxy-terminal collagen crosslinks), and
consequently indicate bone remodeling status; which is
considered the major mechanism underlying osteopor-
osis [9]. BTMs have been proposed to be independent
predictor factors for osteoporosis [10–13] and osteopor-
otic fractures [14–16]. It has been suggested that osteocal-
cin (OC) production is diminished by negative regulation
of osteoblasts in diabetes condition [8, 17]. Also, bone re-
sorption markers such as carboxy-terminal collagen cross-
links (CTX) has been proposed as a predictive factor of
bone fracture in diabetes patients [18].
Several studies have implicated that BTMs are more
sensitive than BMD in estimating fracture risk in pa-
tients with diabetes owing to linkage between BTMs and
glucose metabolism [19, 20].
However, few studies address the association between
BTMs and diabetic complications. We hypothesize that
circulating levels of BTMs can be helpful for manage-
ment of osteoporosis and prevention of bone fracture in
presence of diabetes complications.
The aim of this study was to assess whether bone turn-
over markers were associated with diabetes micro-vascular
complications. Moreover, the possible association between




Between July 2012 and September 2013, 204 adults with
type 2 diabetes mellitus,104 patients with retinopathy
and or nephropathy and 100 patients without retinop-
athy and nephropathy were recruited in this case–con-
trol study from a referral diabetes clinic that is affiliated
with the Tehran University of Medical Sciences. The
study was approved by the Ethics Committee of the
Endocrinology and Metabolism Research Institute. A
comprehensive questionnaire was used and written in-
formed consent was obtained from all participants.
The inclusion and exclusion criteria, retinopathy and
nephropathy diagnosis criteria of the study population
have been described previously [21–23].
The diagnosis of type 2 diabetes was carried out and/
or confirmed following the American Diabetes Associ-
ation criteria (ADA) [24], which includes a fasting blood
glucose ≥126 mg/dL on two separate occasions, random
(non-fasting) blood glucose ≥200 mg/dL on two separate
occasions or a blood glucose >200 mg/dL at 2 h during
a standard oral glucose tolerance test.
Retinopathy and nephropathy definition
All patients were type 2 diabetes without any history of
cancer or chronic disorders. The diagnosis of retinopathy
was carried out according to the American Academy of
Ophthalmology recommendations [25]. According to pre-
viously described definitions, a urine albumin-to-creatinine
ratio was determined from a random urine collection of all
patients and classified as normal (urine microalbumin: cre-
atinine ratio ≤ 30 μg/mg), micro albuminuria (urine micro-
albumin: creatinine ratio >30 μg/mg and ≤ 299 μg/mg) and
macro albuminuria (urine microalbumin: creatinine ratio ≥
300 μg/mg) at least on two separate occasions.
The control subjects were diabetic patients with urin-
ary albumin excretion values within the normal range,
without retinopathy.
Diabetes risk factor definition
Diabetes risk factors were defined based on ADA criteria
[24]. Hypertension was defined in subjects with a BP ≥
140/90 mm Hg or current use of high blood pressure
medications. Dyslipidemia was defined as TG >250 mg/
dL and/or HDL < 35 mg/dL or using lipid-lowering med-
ications. Glycemic control was categorized into poor and
good glycemic control based on HbA1c ≥ 7 % or HbA1c
< 7 %, respectively. Obesity was classified based on
BMI > 30 kg/m2.
Data collection and measurements
Demographic and clinical characteristics including sex,
age, age at diabetes diagnosis, diabetes duration, cigarette
smoking status, and current use of medications were
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obtained by a questionnaire. Height and weight were mea-
sured using standard anthropometric techniques. Body
mass index was calculated as body weight (kg)/(height
(m2). Blood pressure was measured twice after a 10 min
seated rest. Blood samples were collected after an over-
night fasting. The sera were kept at −80 °C until analysis.
Serum biochemical parameters including glucose, total
cholesterol (TC), high-density lipoprotein (HDL), low-
density lipoprotein (LDL), triglyceride (TG), blood urea
nitrogen (BUN), uric acid, and creatinine (Cr), aspartate
aminotransferase (AST), alanine aminotransferase (ALT)
and urine microalbumin and creatinine levels were mea-
sured by enzymatic colorimetric assay [Pars-Asmun kits,
Iran] using an auto analyzer [Hitachi 902, Japan]. The
serum insulin level was measured by an immunoenzymo-
metric assay [Monobind Inc., USA]. The intra- and inter-
assay coefficients of variation (CVs) for insulin were 5.9 %
and 9.2 %, respectively. Glycated hemoglobin (HbA1c)
level was assessed using ion exchange chromatography
with a DS5 set [DREW, United Kingdom].
Intact parathyroid hormone (PTH), OC and CTX were
measured using electrochemiluminescence assay (Roche).
In electrochemiluminescence assay for OC a large N-
terminal midfragment was recognized in addition to the
intact molecule.
Serum 25(OH)D was measured by radioimmunoassay
(RIA) using a Biosource kit (Biosource Europe SA,
Belgium); intra- and inter-assay coefficients of variation
(CV) were 5.2 % and 7.5 %, respectively. P1NP was mea-
sured by quantitative sandwich enzyme immunoassay
technique (intra- and inter-assay CV was <8 % and <10 %)
(Cusabio).
Estimating GFR was calculated based on CKD EPI
Equation; for Cr > 61.9 μmol/l [if female]: GFR =
144 × (Scr/61.9)
-1.209 × (0.993)Age, for Cr > 79.6 μmol/l [if
male] GFR = 141 × (Scr/79.6)
-1.209 × (0.993)Age. In our
population study, serum Cr levels were over 61.9 μmol/l
in women and over 79.6 μmol/l in men.
Statistical analysis
Statistical analysis was performed using SPSS software
(version 16). As certain data, including fasting serum
blood glucose, LDL, TC, TG, PTH, insulin, Cr, uric-acid,
OC, CTX, and P1NP levels did not have normal distri-
butions in case or control group; log transformation was
applied to correct their normality distribution.
Student’s t-test was used to compare the differences in
serum levels of bone turnover markers in diabetic pa-
tients with and without micro-vascular complications.
ANOVA and post Hoc tests were applied to examine the
difference between bone turnover markers in patients
with diabetic retinopathy (DR), diabetic nephropathy (DN),
and both DR/DN. A Pearson correlation was used to deter-
mine correlation between bone turnover markers and
metabolic markers. A general linear model was used to de-
termine an independent association between bone turn-
over markers and diabetes micro-vascular complications.
Numerical variables were reported as the mean ± stand-
ard error, and categorical variables were presented as
percentages. Two-tailed p-values less than 0.05 were con-
sidered significant.
Results
A total of 204 diabetic patients were enrolled in this
study that included 104 patients with DR and/or DN
(case group) and 100 patients without DR and/or DN
(control group). The baseline characteristics of diabetic
patients with and without the complications are shown in
Table 1. Case group was tended to be older, with a longer
duration of diabetes. There were not significant differ-
ences in the prevalence of hypertension, dyslipidemia and
obesity (p > 0.05). There was early age of diagnosis among
case group but not statistically significant (p = 0.1).
Table 2 shows the means of metabolic markers and all
BTMs in serum samples collected from the participants
in case and control groups. Compared to the control
group, there were no statistically significant differences
in FBS, insulin, TC, LDL, Insulin and liver function tests
(AST, ALT). However, the case group had significantly
lower HDL and higher HbA1c, TG, uric acid, BUN, Cr
and eGFR compared with control group (p < 0.05).
In addition, there was a significant increase trend in
serum PTH levels (p = 0.0001) and a tendency to be
lower in serum levels of 25(OH) D among patients in
case group (p = 0.04). Also, after adjusting for age, sex
and BMI, there was significant difference in serum levels
of PTH and 25(OH) D between patients in case and
control groups (p = 0.005, p = 0.042, respectively).
Bone markers and diabetes microvascular complications
Patients in case group had higher serum levels of P1NP
and CTX, although the results were not statistically signifi-
cant (p = 0.33, p = 0.058, respectively). However, patients in
case group had significantly higher serum levels of OC
compared to patients in control group (p = 0.0001). The
result was consistence even after adjusting for age, BMI,
and sex (p = 0.001).
To investigate the serum levels of bone markers with
respect to type of micro-vascular complication, patients
were stratified according to retinopathy or nephropathy
or both complications (Fig. 1). The serum levels of OC
were higher in patients with both DR/DN compared
with patients with only DN or only DR (p = 0.0001,
p = 0.02, respectively) (Fig. 1a).
In addition, in patients with both complications, there
were significantly higher serum levels of CTX compared
with patients with only retinopathy (p = 0.003). But there
were not significantly differences in the serum levels of
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CTX between patients with both complications and
those with only nephropathy. Notable, in patients with
only nephropathy, the serum levels of CTX were higher
than patients with only retinopathy (p = 0.025) (Fig. 1b).
Bone markers and metabolic factors
To investigate correlation between bone markers and
metabolic factors, Pearson correlation was performed in
all subjects. Among bone markers, there was significant
positive correlation between P1NP with ALT levels (r =
0.24, p = 0.04) and negative correlation with vitamin D
levels (r = −0.18, p = 0.01). In addition, there was positive
correlation between P1NP and PTH but not significant
(r = 0.14, p = 0.06). Regarding OC, there were significant
positive correlations between OC with Cr (r = 0.55, p =
0.0001), BUN (r = 0.57, p0.0001), uric-acid (r = 0.25, p =
0.002), PTH (r = 0.53, p = 0.0001), and urine albumin/
creatinine ratio (r = 0.38, p = 0.0001) and negative correl-
ation with eGFR (r = −0.48, p = 0.0001).
Significant positive correlations were observed between
CTX with PTH levels (r = 0.40, p = 0.0001), Cr (r = 0.34, p
= 0.0001), BUN levels (r = 0.42, p = 0.0001) and urine albu-
min/creatinine ratio (r = 0.23, p = 0.001) and negative
correlation with eGFR (r = −0.26, p = 0.0001). We found
no correlation between bone markers and other metabolic
factors (p > 0.05). The correlations between metabolic
factors and bone markers in case and control groups are
summarized in Table 3. In case group, there were
significant correlations between CTX and OC with kidney
function factors (BUN, Cr, eGFR) as well as PTH levels (p
< 0.01). In control group, there was only significant correl-
ation between OC and CTX with BUN levels (p < 0.05).
A general lineal model was used to control confound-
ing variables. After adjusting for age, sex, obesity and
diabetes complications, the analysis showed not signifi-
cant association between bone markers (OC, CTX,
P1NP) and metabolic risk factors including FBS, TG,
TC, HDL, LDL, HbA1c, and insulin (p > 0.05). However,
in this model, there was significant association between
OC and CTX with PTH (p = 0.0001). Among kidney
function markers such as BUN, eGFR, and uric acid;
there was significant positive association between OC
and CTX with BUN (p = 0.0001).
In this model, there was no significant association be-
tween bone markers OC and CTX with eFGR (p = 0.52,
p = 0.20, respectively).
We found no significant correlation between serum
levels of HbA1c, duration of diabetes with bone turnover
markers in case or control groups (p > 0.05) even after
adjusting age, sex and BMI.
Discussion
While numerous studies addressed bone markers in
T2DM and T1DM [26–28], a few studies compared the
difference of bone markers in the context of microvascu-
lar complications [29, 30]. Here, we present the
Table 1 The baseline characteristics and diabetic risk factors of type 2 diabetic patients with and without micro-vascular
complications





Age (years) 58.28 ± 0.60 55.36 ± 0.63 0.001
Sex
Men 54 (60) 41 (41.0) 0.11
Female 50 (40) 59 (59)
Duration of diabetes (years) 15.45 ± 0.67 10.21 ± 0.62 0.001
Age of onset (years) 43.22 ± 0.85 45.04 ± 0.75 0.11
Hypertension 76 (73.1) 62 (62.0) 0.09
Dyslipidemia 82 (78.8) 87 (87) 0.12
Obesity 44 (43.1) 37 (37) 0.37
Poor Glycemic control 68 (66) 58(58) 0.23
Albuminuria 53 (51) - -
Physical activity
Vigorous (30 min, at least 5 days per week)





Low (10–30 min, less than 3 days per week) 19 (18.3) 19 (19) 0.65
Only daily activity 26 (25) 30 (30)
Numerical variables were reported as the mean ± standard error, and categorical variables were presented as number (percentage)
Hypertension was defined in subjects with a BP ≥ 140/90 mm Hg or current use of high blood pressure medications. Dyslipidemia was defined as TG >250 mg/dL
and/or HDL < 35 mg/dL or using lipid-lowering medications. Poor glycemic control was defined as HbA1c ≥ 7 %. Obesity was classified based on BMI > 30 kg/m2
DR Diabetic Retinopathy, DN Diabetic Nephropathy
Maghbooli et al. Journal of Diabetes & Metabolic Disorders  (2016) 15:51 Page 4 of 8
difference in bone markers and their association with
other metabolic parameters in T2DM with and without
microvascular complications.
Our study reveals that bone markers including OC
and CTX manifest increased values in T2DM patients
with microvascular complications compared with
diabetic patients without complications. Along with
increased trend in bone markers, we observed in-
creased level of PTH and decreased level of vitamin
D in diabetic patients with microvascular complica-
tions. Our findings suggest that microvascular compli-
cations might involve in disturbance of bone markers
and subsequently bone quality in diabetic patients
although not provide a direct causality.
Table 2 The biochemical metabolic and bone turnover markers in diabetic patients who developed microvascular complications
compared with those without microvascular complications
Baseline characteristics With DR and/or DN
N = 104 (mean ± SE)
Without DR /DN
N = 100 (mean ± SE)
p-value
FBS (mg/dL) 134.81 ± 1.51 134.92 ± 1.03 0.98
Insulin (μU/L) 11.51 ± 0.15 9.08 ± 0.21 0.068
HbA1c (%) 8.08 ± 0.19 7.37 ± 0.14 0.003
TG (mg/dL) 132.55 ± 0.16 115.16 ± 0.15 0.036
HDL (mg/dL) 44.10 ± 1.09 49.58 ± 1.05 0.0001
LDL (mg/dL) 80.19 ± 0.13 79.11 ± 0.13 0.78
TC (mg/dL) 148.91 ± 0.12 148.99 ± 0.12 0.99
Cr (μmol/L) 113.42 ± 0.14 87.51 ± 0.13 0.0001
BUN (mg/dL) 20.59 ± 0.14 15.18 ± 0.13 0.0001
Uric-acid (mg/dL) 5.63 ± 0.15 5.63 ± 0.13 0.002
eGFR 89.02 ± 3.07 76.18 ± 2.70 0.0001
AST (U/L) 17.79 ± 0.23 20.65 ± 0.24 0.56
ALT (U/L) 21.73 ± 0.25 21.73 ± 0.23 0.13
PTH (pg/mL) 46.64 ± 3.91 34.22 ± 1.44 0.001
25(OH)D (nmol/L) 27.24 ± 2.17 33.25 ± 1.99 0.04
OC (ng/mL) 17.88 ± 0.19 13.32 ± 0.16 0.0001
CTX (ng/mL) 0.28 ± 0.02 0.24 ± 0.01 0.06
P1NP (pg/mL) 86.19 ± 0.36 71.52 ± 0.40 0.33
DN Diabetic nephropathy, DR Diabetic retinopathy, FBS fasting blood sugar, TG triglyceride, HbA1c hemoglobin A1c, HDL high-density lipoprotein, LDL low-density
lipoprotein, TC total cholesterol, Cr creatinine, BUN blood urea nitrogen, AST aspartate aminotransferase, ALT alanine aminotransferase, PTH Intact parathyroid
hormone, 25(OH)D 25 (OH) vitamin D, OC osteocalcin, CTX carboxy-terminal collagen crosslinks, P1NP procollagen I aminoterminal propeptide, eGFR estimated
glomerular filtration
Fig. 1 Osteocalcin (a) and beta-crosslaps (b) in patients with retinopathy (DR), nephropathy (DN) and both complications (DR/DN). Reference
group: Type 2 diabetic patients without DR and DN. *p-value < 0.05, **p-value < 0.01, ***p-value < 0.001
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In consistent to our study, Inukai and colleges’ evaluated
OC, vitamin D and PTH in type 1 diabetes patients with
nephropathy. They reported a significant positive correl-
ation between PTH and OC and a positive correlation
between OC and urine albumin excretion in diabetes pa-
tients. They revealed HbA1C levels were not correlated
with OC levels. Also, they found vitamin D levels were de-
creased and OC levels were increased in diabetic subjects
with proliferative retinopathy or with micro- or macro-
albuminuria. However, they did not find any significant
correlation between OC and vitamin D levels [29]. Our re-
sult showed that PTH levels had positive correlation with
OC as a bone formation and with CTX as a bone resorp-
tion in diabetes patients who suffering of DR/and or DN.
Also PTH levels had significant correlation with urine al-
bumin/creatinine ratio. The correlation between circulat-
ing PTH and bone markers may modulate bone turnover
markers in diabetes patients with micro-vascular compli-
cations. It has suggested circulating PTH is important in
restoring the reduced OC levels in diabetic patients, prob-
ably as a reflection of bone remodeling [29].
A few primary studies, investigated hydroxyproline ex-
cretion as a bone resorption markers in type 1 and type
2 diabetes patients with micro-vascular complications
[31]. They reported the bone marker did not differ be-
tween diabetes patients with or without retinopathy or
neuropathy. But there was positive association between
hydroxyproline excretion and microalbuminuria.
Interestingly, we could observe robust correlation be-
tween bone turnover markers (OC, and CTX) and renal
function markers including BUN, uric-acid and eGFR.
This association remained significant after adjustment
for age, sex and diabetes complications in BUN levels.
So, deterioration of renal function in patients with com-
plications which leads to decreased renal clearance of
bone markers might at least in part explain the increased
value of bone markers in patients with complications.
Our finding also showed no differences in P1NP levels
between diabetes patients with or without micro-vascular
complications [27]. In contrast to our study, Shanbhogue
and colleagues have reported higher level of P1NP in
T2DM with or without micro-vascular complications
compared to respective controls [26].
Most of studies have reported BTMs in diabetic pa-
tients compared to non-diabetic subjects. Generally, they
have suggested that in diabetes condition OC and CTX
productions were reduced. In a study by Chen and col-
leagues on type 2 diabetes patients with nephropathy,
Table 3 Correlation between bone turnover markers and metabolic factors in diabetes patients with and without micro-vascular
complications
With DR and/or DN Without DR /DN
CTX (ng/ml) P1NP (pg/ml) OC (ng/ml) CTX (ng/ml) P1NP (pg/ml) OC (ng/ml) CTX (ng/ml)
Metabolic Factors r p-value r p-value r p-value r p-value r p-value r p-value
FBS (mg/dL) 0.04 0.68 −0.08 0.44 0.01 0.95 0.01 0.92 −0.11 0.33 −0.06 0.60
Insulin ((μU/L) 0.15 0.3 0.22 0.12 0.13 0.37 −0.11 0.37 −0.17 0.17 −0.20 0.10
HbA1c (%) 0.07 0.51 −0.02 0.87 −0.04 0.68 0.11 0.28 −0.13 0.24 −0.04 0.68
TC (mg/dL) −0.03 0.74 −0.06 0.56 −0.04 0.69 −0.09 0.36 −0.08 0.47 −0.11 0.32
HDL (mg/dL) 0.06 0.58 −0.03 0.75 0.09 0.37 −0.008 0.94 0.08 0.44 0.03 0.79
LDL (mg/dL) −0.07 0.49 −0.07 0.50 −0.09 0.36 −0.08 0.41 −0.04 0.74 −0.08 0.48
TG (mg/dL) −0.01 0.92 −0.01 0.93 −0.06 0.57 −0.23b 0.03 −0.12 0.29 −0.15 0.17
BUN (mg/dL) 0.09 0.41 0.63a 0.0001 0.50a 0.0001 0.16 0.12 0.27b 0.01 0.21b 0.04
Cr ((μmol/L) 0.07 0.5 0.65a 0.0001 0.48a 0.0001 0.11 0.31 0.15 0.18 0.01 0.95
uric acid 0.11 0.32 0.28a 0.006 0.13 0.19 0.04 0.69 0.0001 0.99 −0.07 0.51
eGFR −0.05 0.61 −0.58a 0.0001 −0.40a 0.0001 −0.10 0.32 −0.13 0.24 0.03 0.76
Urin-Alb/Cr (mg/g) −0.09 0.39 0.39a 0.0001 0.26b 0.01 0.09 0.36 −0.17 0.12 −0.17 0.10
PTH (ng/mL) 0.16 0.13 0.59a 0.0001 0.54a 0.0001 0.08 0.48 0.17 0.11 0.01 0.95
25(OH)D −0.17 0.1 −0.06 0.59 −0.11 0.30 −0.18 0.08 −0.01 0.91 −0.02 0.86
AST (mg/dL) 0.14 0.44 .48a 0.006 0.38b 0.03 0.19 0.22 −0.02 0.88 −0.14 0.38
ALT (mg/dL) 0.29 0.12 0.06 0.74 0.25 0.15 0.26 0.10 −0.19 0.26 −0.31 0.05
R Pearson correlation, DN Diabetic nephropathy, DR Diabetic retinopathy, FBS fasting blood sugar, TG triglyceride, HbA1c hemoglobin A1c, HDL high-density
lipoprotein, LDL low-density lipoprotein, TC total cholesterol, Cr creatinine, BUN blood urea nitrogen, AST aspartate aminotransferase, ALT alanine aminotransferase,
PTH Intact parathyroid hormone, 25(OH)D 25 (OH) vitamin D, OC osteocalcin, CTX carboxy-terminal collagen crosslinks, P1NP procollagen I aminoterminal propeptide,
eGFR estimated glomerular filtration
aCorrelation is significant at the 0.01 level (2-tailed)
bCorrelation is significant at the 0.05 level (2-tailed)
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OC levels were higher than patients without DN. How-
ever, compared to healthy subjects, diabetes patients
with or without DN had decreased serum OC [2].
Along with increased trend in bone markers, we observed
increased level of PTH and decreased level of vitamin D in
diabetic patients with microvascular complications. In our
study, we did not assess BTMs in healthy group.
Although the patients with complications had higher
level of HbA1c and insulin, we could not find any
correlation between hyperglycemia markers and bone
markers after adjustment for age, sex, obesity and dia-
betes complications. Conversely, a recent study has indi-
cated the role of OC in replication of beta-cells and
insulin secretion and on the other hands role of insulin
in activation of OC [32]. The physiologic relevance of
this finding has been confirmed by other studies which
demonstrated the association between hyperglycemia
and bone markers [33, 34]. Nevertheless in agreement
with our findings, others have reported no association
between bone markers and hyperglycemia. In parallel,
another study which examined the effect of a glucose-
lowering agents on bone homeostasis in a streptozotocin
(STZ)-induced hyperglycemia mouse model, has re-
vealed no alteration in microstructure and bone markers
in spite of improving blood glucose [35]. A similar clin-
ical study on newly diagnosed T2DM, has reported that
consumption of antihyperglycemic agents had no impact
on bone markers while they could improve glucose con-
trol in the patients [36]. Our results confirmed the latter
studies and suggest that bone turnover markers are not
merely influenced by hyperglycemia markers in diabetic
patients. Therefore, in the present study, it appears that
deleterious effects of micro-vascular complications
might not arise from poor hyperglycemia control in
these patients.
There are some limitations in our study. The design of
our study could not provide a direct causality of diabetes
complications and BMTs. However, further studies are
needed to investigate the effect of diabetes complications
on BMTs and bone status. Consistent with previous stud-
ies, our result showed that duration of diabetes signifi-
cantly differed in patients with and without DR. To
control for selection bias due to further match in two
groups, we used the univariate model to adjust all con-
founding variables such as age, sex, and diabetes duration.
Conclusions
To sum, OC and CTX circulated in higher amounts in
T2DM patients with microvascular complications and were
not correlated with metabolic markers. In addition, contri-
bution of microvascular complications in bone marker
disturbance is likely independent of impaired glucose
homeostasis. However, we observed a significant correl-
ation between bone turnover markers and renal function
indices. Also PTH levels had significant correlation with
CTX and OC as well urine albumin/creatinine ratio. It is
likely that circulating PTH is important to keep OC or
CTX balance in diabetic patients, probably as a reflection
of bone remodeling. Our findings suggest that kidney
markers could modulate bone-remodeling in diabetes pa-
tients. Little is known on the effect of kidney function on
BTM in diabetes patients, further studies are needed.
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